

1 **Full title:**

2 **Pulmonary haemorrhage as a frequent cause of death among patients with**
3 **severe complicated Leptospirosis in Southern Sri Lanka**

4 **Short title:**

5 **Pulmonary haemorrhage and severe Leptospirosis**
6

7 ¹Fonseka CL, ¹Dahanayake NJ, ²Mihiran DJD, ²Mithunika AWK, ²Nawanjana HLL,
8 ²Wickramasuriya HS, ⁴Wijayarathne WMDGB, ⁴Sanjaya K, ¹Bodinayake CK.

9
10 ¹Department of Internal Medicine, Faculty of Medicine, University of Ruhuna, Galle

11 ²Faculty of Medicine, University of Ruhuna, Galle

12 ³Department of Microbiology, Faculty of Medicine, University of Ruhuna, Galle

13 ⁴Department of Limnology and Water Technology, Faculty of Fisheries and Marine Sciences &
14 Technology, University of Ruhuna

15 Corresponding author: fonseka.lakmal@gmail.com

16
17 **Abstract**

18 **Background:** Leptospirosis is a tropical disease associated with life threatening complications.
19 Identifying clinical and investigation-based parameters that predict mortality and morbidity is vital
20 to provide optimal supportive care. **Methods:** We conducted a prospective observational study in
21 an endemic setting, in the southern Sri Lanka. Consecutive patients having complicated
22 leptospirosis were recruited over 18 months. Clinical, investigational and treatment data were
23 collected and the predictors of mortality were analysed. **Results:** Out of 88 patients having
24 complicated leptospirosis, 89% were male. Mean age was 47yrs (± 16.0). Among the total, 94.3%
25 had acute kidney injury, 38.6% had pulmonary haemorrhages, 12.5% had fulminant hepatic

26 failure, 60.2% had hemodynamic instability and 33% had myocarditis. An acute significant
27 reduction of haemoglobin (Hb) was observed in 79.4% of patients with pulmonary haemorrhage.
28 The mean Hb reduction of patients with pulmonary haemorrhage was 3.1g/dl. The presence of
29 pulmonary haemorrhage (PH) and hemodynamic instability within first 48 hours of admission
30 significantly predicted mortality($p<0.05$) in severe Leptospirosis. Additionally, within first 48
31 hours of admission, elevated SGOT, presence of atrial fibrillation, presence of significant
32 haemoglobin reduction, higher number of inotropes used, prolonged shock, invasive ventilation
33 and admission to ICU significantly predicted mortality. Out of organ complications in the first week
34 of illness, pulmonary haemorrhage and fulminant hepatic failure (FHF) combination had
35 significant adjusted odds of mortality (OR=6.5 and 4.8, $p<0.05$). Six patients with severe
36 respiratory failure due to PH underwent ECMO and four survived. The overall mortality in
37 complicated leptospirosis was 17%. In PH and FHF, the mortality rate was higher reaching 35.4%
38 and 54.5%, respectively. **Conclusions:** Within first 48 hours of admission, organ complications
39 such as pulmonary haemorrhage and haemodynamic instability and other parameters such as atrial
40 fibrillation, acute haemoglobin reduction, elevated SGOT level could be used as early parameters
41 predictive of mortality in severe Leptospirosis. PH and FHF within the first week of admission in
42 leptospirosis are associated with high morbidity and mortality requiring prolonged ICU care and
43 hospitalisation. Above parameters could be used as parameters indicating severity for triaging and
44 intensifying treatment. Using ECMO is a plausible treatment option in patients with severe
45 pulmonary haemorrhage.

46 **Keywords:** Leptospirosis, Pulmonary Haemorrhage, Lung haemorrhage, alveolar haemorrhage
47 Fulminant Hepatic Failure, Extracorporeal Membrane Oxygenation, Predictors of mortality

48 **Author summary**

49 Leptospirosis is a tropical infectious disease predominantly affecting the lower socioeconomic
50 groups in Sri Lanka. It is associated with significant morbidity and mortality, especially in an
51 endemic setting. Hence, it is vital to identify clinical and biochemical parameters that can predict
52 mortality for triaging and for escalation of care. We observed that pulmonary haemorrhage,
53 myocarditis, hemodynamic instability and hepatic dysfunction are frequent complications of
54 leptospirosis in southern Sri Lanka. Additionally, we identified that mortality was associated with
55 the presence of two major complications of leptospirosis: pulmonary haemorrhage and

56 haemodynamic instability. Therefore, early detection of these two complications along with other
57 parameters that predict mortality such as elevated SGOT levels on admission, acute haemoglobin
58 reduction, atrial fibrillation, prolonged shock and need for invasive ventilation would assist to
59 recognise critically ill patients. Within the first week of admission, PH and development of FHF
60 predicted mortality. One-third our population had acute kidney injury in isolation and they had
61 lesser mortality. Other organ complications were almost always detected in combination and were
62 associated with a higher mortality. Pulmonary haemorrhage was detected in one-third of patients
63 and the majority warranted intensive care. Other than usual treatment modalities, ECMO
64 (Extracorporeal Membrane Oxygenation) was used in six patients with critical respiratory failure
65 due to pulmonary haemorrhage, where four survived. Out of the total group of complicated
66 leptospirosis, in excess of one-third required intensive care treatment and 17% succumbed.
67 Additionally, we mapped the leptospirosis prevalence rate in Galle district, and observed that
68 severe cases are detected in specific localities. These features are helpful in early detection of
69 severe disease and proactive management for those who are having predictors of mortality.

70

71 **Introduction**

72 Leptospirosis has emerged as a major health threat in tropical and even in sub-tropical settings,
73 estimated to infect more than a million people with approximately 60,000 deaths annually[1].
74 Natural disasters and extreme weather events including floods are now recognized to precipitate
75 leptospirosis related epidemics [2] and its emergence in tropical settings is observed even in Sri
76 Lanka[3]. Severe leptospirosis is characterized by dysfunction of multiple organs including the
77 liver, kidneys, lungs, and brain. The combination of jaundice and renal failure was commonly
78 known as Weil's disease[4].

79 The major burden attributed to leptospirosis is due to its severe life-threatening manifestations
80 such as acute renal failure, myocarditis, pulmonary haemorrhage and liver involvement. Out of the
81 life-threatening manifestations, pulmonary haemorrhage (PH) is recognized as the most fatal. This
82 life-threatening complication was observed to be prevalent in several leptospirosis endemic
83 countries such as Nicaragua, El Salvador, Sri Lanka and Greece [5-8]. The case fatality for
84 pulmonary haemorrhage syndrome was reported to be more than 50% [9], but in an endemic setting

85 it could be as high as 100%[10-12]. A recent review noted 1.4-45.4% of lung involvement among
86 hospitalized patients in Sri Lanka[13], and a recent study done in southern Sri Lanka mentioned
87 an incidence just above 60%[14].

88 Different studies have mentioned parameters or manifestations that can be associated with
89 mortality from Leptospirosis. Few studies have mentioned that altered mental status, oliguria, and
90 respiratory insufficiency, hypotension, arrhythmias were independently associated with death[15-
91 17]. Out of organ related complications, acute kidney injury (AKI) is found to be the most common
92 manifestation with a median series mortality around 10%[18]. Myocarditis was found in 7–15%
93 of confirmed cases in Sri Lanka[19, 20]. Hepatic involvement is common and can commonly
94 present as slight disturbances in serum liver function tests. However, fulminant hepatic failure is
95 occasionally reported as a recognised complication in a few instances of severe leptospirosis[21].
96 It was evident that frequency of the complication could vary depending on the infecting serovar
97 and geographic location.

98 In severe cases of pulmonary haemorrhage, some preferred using advanced therapeutic modalities
99 such as plasmapheresis and ECMO. Although these techniques were previously reserved for
100 developed countries, currently there are attempts to use these in developing countries where
101 leptospirosis is endemic[22]. Currently, there is a paucity of knowledge on usage of ECMO in
102 patients with pulmonary haemorrhage in an endemic tropical setting, only reported several case
103 reports[22].

104 In our study, we describe morbidity, mortality and their predictors in a potentially severe group of
105 leptospirosis who had organ complications, excluding relatively benign mild cases of leptospirosis
106 without significant organ involvement. Additionally, we describe details from a large prospective
107 case series of critically ill patients with pulmonary involvement who required ECMO.

108 **Methods**

109 **Study sample**

110 A prospective observational study was conducted at the Teaching Hospital Karapitiya (THK),
111 Galle, the largest tertiary care centre in southern Sri Lanka, for 18 months, from March 2017 to
112 September 2018. THK is the main referral center for complicated leptospirosis and for ECMO,
113 due to its geographic location surrounding paddy farming communities. All consenting

114 consecutive patients meeting the criteria for complicated leptospirosis (with at least single organ
115 involvement) as defined below were recruited from all medical units, emergency care unit and
116 intensive care units(ICU) of THK. The criteria included patients with documented fever or a
117 history of fever within 7 days of admission with or without myalgia with one or more of the
118 following: evidence of acute renal insufficiency without prerenal etiology: creatinine >1.5 mg/dL
119 (130 μ mol/L) and /or urine output less than 500mL/24h with active urinary sediments (at least two
120 of WBC, RBC and albumin on dipstick or >5 RBC/WBC per HPF), evidence of respiratory failure:
121 Respiratory rate >28 cycles per min, evidence of hypoxia requiring oxygen, or requiring non-
122 invasive or mechanical ventilation, evidence of spontaneous hemorrhage, pulmonary hemorrhage
123 on chest radiograph or hemoptysis, conjunctival hemorrhage, epistaxis, hematuria, hematemesis,
124 hemochezia or melena, unexplained vaginal bleeding, or petechiae), evidence of cardiac
125 arrhythmias or ECG changes suggestive of myocarditis or new echocardiographic abnormalities
126 suggestive of myocarditis, evidence of hepatic dysfunction - Clinical jaundice or elevated bilirubin
127 (total bilirubin >2mg/dL or 51.3 μ mol/L) or laboratory evidence of hepatitis (transaminases
128 elevated above 2 times the upper limit of normal). Patients whose age less than 12 years, patients
129 who are unable or unwilling to give consent for participation, leukopenia within 48 hours prior or
130 after hospital admission, positive rapid test, virology or serology for Dengue or infections other
131 than leptospirosis, evidence of focal bacterial infection as an aetiology of fever (i.e., urinary tract
132 infection/ pyelonephritis, cellulitis, sinusitis, lobar pneumonia), evidence of end organ failure
133 (renal, cardiac, respiratory) due to other etiologies unrelated to the current illness were excluded
134 from the study.

135 **Definitions of complications**

136 Oliguric renal failure was defined as urine output <0.5 ml/kg/hr and non-oliguric renal failure
137 when urine output >0.5 mL/kg/hr. Pulmonary haemorrhage (PH) was defined from the presence
138 of hypoxia (SpO₂ <92%, paO₂ < 80 mmHg/10.7 kPa) / requirement of oxygen by non-invasive or
139 invasive methods with the presence of bilateral diffused alveolar shadows and/or drop in
140 haemoglobin. Acute liver failure or fulminant hepatic failure was defined as the presence of
141 PT/INR >1.5 and/or presence of hepatic encephalopathy. Cardiac involvement was defined by the
142 presence of elevated troponin levels, changes in electrocardiogram or presence of arrhythmias or

143 echocardiographic changes. Significant acute haemoglobin reduction due to bleeding was defined
144 as ≥ 2 g/dl reduction of haemoglobin within 48 hours.

145 **Data collection**

146 Clinical and epidemiological data were collected prospectively, using an interviewer administered
147 questionnaire by a trained research assistant by conducting direct interviews of patients, and from
148 hospital records after obtaining written informed consent from study participants. Laboratory and
149 clinical parameters on first 48 hours of admission were used to analyse predictors of mortality.
150 When the patient was in critical condition, the consent was obtained from the next-of-kin. The
151 patients were visited every other day by the investigators to record clinical data and laboratory
152 data. Follow-up was done by a brief assessment at the hospital performed one month after
153 discharge from the hospital or by a telephone conversation.

154 **Laboratory conformation**

155 Laboratory confirmation was based on the WHO LERG report, by symptoms consistent with
156 leptospirosis and a single Microscopic Agglutination Test (MAT) titre $\geq 1:400$ and/or by detection
157 of *Leptospira* DNA by PCR and/or by the presence of IgM antibodies [23]. Leptospirosis PCR and
158 MAT (15 pathogenic serovar panel) was performed at Medical Research Institute, Colombo, Sri
159 Lanka.

160 **Spatial distribution of leptospirosis occurrence**

161 GPS location of location of probable exposure to leptospirosis or home was recorded during the
162 study. The spatial distribution of the patients was overlaid with the local Divisional secretariat
163 (DS) division map of the all districts and the prevalence of leptospirosis cases per hundred
164 thousand people in each DS division was illustrated using ArcGIS 10.3.

165 **Statistical testing**

166 All data were analyzed with SPSS version 26.0. Results were expressed by mean \pm standard
167 deviation (SD) or percentages. Comparison between the two groups was performed using
168 Pearson's Chi-square test and Student's T test. Mann-Whitney test was used for parameters with
169 a non-normal distribution. A logistic regression model was used for quantitative variables for
170 binary outcome of mortality. Unadjusted odds ratios (OR) and 95% confidence intervals (CI) were

171 calculated. A multivariate logistic regression (stepwise forward and backward analysis) was
172 performed to analyze the possible risk factors associated with mortality. Significance level was set
173 at 5 % (p value ≤ 0.05).

174 **Results**

175 One hundred and twenty-two patients with complicated leptospirosis were recruited to the study.
176 Eighty-eight were eligible and the diagnosis was confirmed by PCR and/or MAT testing. Among
177 them, mean age was 47(± 16.0) years, and 89% were male. Almost all patients had fever (97.7%)
178 on presentation, and myalgia (81.8%), arthralgia (78.4%), vomiting (46.6%) and headache (62.5%)
179 were other common symptoms. Eighty-three percent had a history showing exposure to
180 leptospirosis. Thirty-two (36.4%) patients had received ICU care. Among them, the mean duration
181 of hospitalization was 8.07(SD \pm 5.9) days and the mean duration of ICU care was 6.73(SD \pm 4.9)
182 days. The case fatality rate of the study sample was 17% with 15 deaths, including one patient who
183 succumbed on admission to the hospital.

184 **Complications associated with Leptospirosis (Table 1)**

185 **Acute kidney injury**

186 Among the study group, acute kidney injury was the most common complication. Out of 88
187 patients, 83(94.3%) developed AKI. Among the group who had AKI, 73.9% had oliguric renal
188 failure and 15.9% had non-oliguric renal failure. Out of the total, 30.7% (n=27) had only AKI.

189 **Pulmonary Haemorrhage**

190 Pulmonary haemorrhage (PH) was detected in 34(38.6%) patients. All of them had significant
191 hypoxia and bilateral diffuse alveolar opacities. Out of them, 26.1% had cough and shortness of
192 breath. Seven (8%) complained of haemoptysis on admission to the hospital. Twenty-four (70.6%)
193 had bilateral diffused involvement in the chest radiograph and the rest (29.4%) had patchy bilateral
194 alveolar shadows. Among patient who developed PH, all required supplementary oxygen, 15
195 (44.1%) were on non-invasive ventilation, 29 (79.4%) required intubation and ventilation.

196 **Hemodynamic instability**

197 Fifty-three (60.2%) had hemodynamic instability (hypotension with blood pressure $\leq 90/60$) and
198 47 (53.4%) patients required usage of at least one inotrope during the course of treatment. Out of
199 them, in 57.4%, 25.5%, 17% patients required one, two, three or more types of inotropes,
200 respectively, to gain hemodynamic stability.

201 **Cardiac manifestations**

202 Out of total, 33.0% (29/88) had at least a single indicator of cardiac involvement. Elevated
203 Troponin, abnormal ECG or an abnormality in echocardiography was detected in 18.2%, 14.8%,
204 11.4%, respectively. Eleven participants (12.5%) had atrial fibrillation during the illness. One had
205 ST elevation myocardial infarction detected on admission.

206 **Hepatic dysfunction**

207 Out of total, 43 (48.9%) patients had hepatic dysfunction evidenced by deranged transaminases,
208 ALP, total bilirubin and/or PT/INR. Thirty (34.1%) had elevated ALT and/or AST and 8 had
209 elevated alkaline phosphate levels at the first 48 hours of the admission. Deranged PT/INR was
210 observed at a later stage of the illness. Eleven (12.5%) patients had evidence of fulminant hepatic
211 failure late (after 48 hours of the illness) during the course of illness. All of these individuals who
212 fulfilled the definition of acute hepatic failure had prolonged hypotension and were supported on
213 multiple inotropes.

214 **Haematological parameters – acute haemoglobin reduction and platelet count**

215 A significant reduction in haemoglobin (Hb) of $>2\text{g/dl}$ within 48 hours was observed in 27 out of
216 34 (79.4%) having PH with a mean maximum Hb reduction of 3.1g/dl (± 1.2 , range = $1.3\text{-}5.9\text{g/dl}$)
217 over 48 hours. Median day of detection of a significant haemoglobin drop was on day 5 after onset
218 of fever (Q1=4, Q3=6 days). In the non-pulmonary haemorrhage group, a minority (16.7%) had
219 significant haemoglobin reduction. The mean significant haemoglobin reduction in this group was
220 1.15g/dl (± 1.09 , range= $0\text{-}4.5$). Median day of detection of a significant haemoglobin drop in the
221 non-PH group was on day 6 after onset of fever (Q1=4.75, Q3=8.75 days). The maximum mean
222 haemoglobin reduction was significantly higher in the PH group than non-PH group ($p < 0.001$).
223 Furthermore, significant hemoglobin reduction in non-PH group has occurred later than the PH
224 group ($p = 0.046$).

225 Among the whole group, 44 (50.0%) and 70 (79.5%) had platelet counts less than 50,000cm³ and
226 less than 100,000 cm³, respectively.

227 **Table 1: Frequency of complications in severe leptospirosis among the study group**

	Number (n=88)	%
Demographic details		
Age, yrs	47(± 16.0)	
Male	78	88.6
Symptoms		
Fever on presentation	86	97.7%
Myalgia	72	81.8%
Arthralgia	69	78.4%
Headache	55	62.5%
Vomiting	41	46.6%
Fatigue	31	35.2%
Calf pain	35	39.8%
Cough	23	26.1%
Hemoptysis	7	8.0%
Shortness of breath	23	26.1%
Abdominal pain	21	23.9%
Yellowing discolouration of eyes	20	22.7%
Diarrhea	27	30.7%

Reduced urine output	39	44.3%
Leptospirosis exposure in history	73	83%
Disease related complications		
Acute kidney injury	83	94.3%
Oliguric	65	73.9%
Non-oliguric	14	15.9%
Pulmonary haemorrhage	34	37.4%
Myocarditis	29	33.0%
Atrial fibrillation	11	12.5%
Hepatic dysfunction	43	48.9%
Fulminant hepatic failure	11	12.5%
Haemodynamic instability	53	60.2%
Intensive care unit admission	32	36.4%
Overall mortality	15	17%

228

229 **Association of the number of major complications with mortality in severe Leptospirosis**

230 Then, we analysed the association of major complications in patients with severe Leptospirosis
231 within the first week after admission. Acute kidney injury, myocarditis, pulmonary hemorrhage,
232 hepatic dysfunction and hemodynamic instability were considered as major complications.

233 **Table 2** reveals the association of major complications among confirmed leptospirosis patients.
234 Twenty-nine (33.0%) patients had at least one complication associated with leptospirosis. Out of
235 them, nearly all (27 patients, 93.1%) had isolated acute kidney injury, one had isolated pulmonary
236 haemorrhages and another had isolated hemodynamic instability mimicking septic shock. In the
237 group of patients who had only two major complications, majority (n=13, 68.4%) had acute kidney

238 injury with hemodynamic instability. Increasing number of complications significantly increased
 239 the admission to ICU, duration of hospital stays and mortality ($p < 0.05$).

240 **Table 2: Morbidity and Mortality in patients having major complications of severe**
 241 **Leptospirosis**

Number of Complications	1 (n=29)	2 (n=19)	3 (n=20)	4 (n=17)	5 (n=3)	p-value
Complications						
AKI	27 (93.1%)	17 (89.5%)	19 (95.0%)	17 (100%)	3 (100%)	0.711
Pulmonary Haemorrhage	1 (3.4%)	1 (5.3%)	13 (65.0%)	16 (94.1%)	3 (100%)	<0.01**
Myocarditis	0	4 (21.1%)	10 (50.0%)	12 (70.6%)	3 (100%)	<0.01**
Fulminant Hepatic Failure	0	1 (5.3%)	0	7 (41.2%)	3 (100%)	<0.01**
Hemodynamic instability	1 (3.4%)	15 (78.9%)	18 (90.0%)	16 (94.1%)	3 (100%)	<0.01**
Morbidity & Mortality						
Admission to ICU	1 (3.4%)	2 (10.5%)	12 (60.0%)	14 (82.4%)	3 (100%)	<0.01**
Duration of ICU care (Days)	2	6.5 (\pm 2.1)	6.1 (\pm 4.4)	8 (\pm 6.1)	5.3 (\pm 3.2)	0.7
Duration of hospital stay	5.5 (\pm 1.8)	7.7 (\pm 4.1)	8.6 (\pm 4.9)	13.2 (\pm 9.6)	6.7 (\pm 2.9)	<0.01**
Mortality	1(3.4%)	1 (5.3%)	4 (20.0%)	6 (35.3%)	3 (100%)	<0.01**

242

243 **Early predictors of mortality in patients with severe Leptospirosis**

244 Clinical and biochemical parameters within first 48 hours of admission were considered for
 245 analysis. Symptoms present on admission were not predictive of mortality, which included
 246 symptoms such as haemoptysis, shortness of breath, abdominal pain etc. However, the presence
 247 of atrial fibrillation, presence of a significant acute haemoglobin reduction, increase number of
 248 inotropes used, prolonged shock, intubation and ventilation, and admission to ICU significantly
 249 predicated mortality in the severe leptospirosis group. Although, platelet, white cell count, serum
 250 bilirubin during admission were not predictive of mortality, high SGOT level on admission (but
 251 not SGPT) level significantly predicted mortality (Table 3).

252 **Association of organ involvement with mortality in severe Leptospirosis**

253 We analysed whether these five major complications were predictive of mortality in patients with
 254 severe Leptospirosis (Table 3). Due to the long hospital stay in certain individuals the
 255 complications within the first week of stay in hospital was considered for this analysis. The
 256 presence of pulmonary haemorrhage (PH), fulminant hepatic failure (FHF) and hemodynamic
 257 instability significantly predicts mortality($p < 0.05$). Additional analysis with stepwise logistic
 258 regression showed that, out of the five complications, PH and FHF combination were most
 259 predictive of mortality.

260 **Table 3: Clinical indices and Major organ complications predictive of mortality in patients**
 261 **with severe leptospirosis. (Logistic regression analysis of predictors of mortality)**

	Unadjusted Odds ratio	p Value	Adjusted Odds ratio	p Value
Clinical Indices				
Presence of high SGOT	5.3 (CI=1.6-17.1)	0.006*		
Atrial fibrillation	4.7 (CI=1.21-17.8)	0.22		
Presence of a significant reduction of Hb (>2g/dl over 48 hours)	5.3 (CI=1.5-18.9)	0.009*		

Number of inotropes used in shock	10.7 (CI=2.5-45.4)	0.001*		
Longer duration of shock / inotrope requirement	2.5 (CI=1.07-5.9)	0.034*		
Intubation and ventilation	18.5 (3.8-89.5)	<0.001**		
Admission to ICU	10.6 (CI=2.7-41.5)	0.001*		
Type of major organ complication				
Pulmonary Hemorrhage	9.3 (CI=2.4-36.1)	<0.001**	6.5 (CI=1.6-27.0)	0.01*
Fulminant Hepatic Failure	9.1 (CI=2.3-35.9)	0.002*	4.8 (CI=1.1-21.0)	0.04*
Hemodynamic instability	12.2 (CI=1.5-97.7)	0.018*	-	
Myocarditis	-	0.07	-	
AKI	-	0.9	-	

262

263 **Comparison of mortality and morbidity in patients having Pulmonary Haemorrhage (PH)**

264 **Table 4** depicts a comparison of clinical characteristics and morbidity and mortality among
 265 patients who had pulmonary haemorrhage compared with those who did not.

266 This shows that females had a significantly higher risk of developing PH than males. The PH group
 267 required significantly higher non-invasive ventilation, intubation and ICU care and had a higher
 268 number of days in ICU and in hospitalization. Out of the patients who had PH, all most all had two
 269 or more major complications and had a significantly higher mortality rate compared to the group
 270 who had no PH (35.3% vs 5.6%). Nearly 80% patients with PH required management in an ICU.
 271 Among the haematological parameters, PH group (71,400/ μ l \pm 46,600) had significantly lower
 272 mean platelets counts on admission (104,000/ μ l \pm 69,300) (p=0.03). However, white blood cell
 273 count on admission was not significantly between the two groups.

274 **Table 4: Characteristics of complications and morbidity among patients having pulmonary**
 275 **haemorrhage (PH) in severe Leptospirosis**

	No PH	PH	p-value
--	-------	----	---------

Number of patients		54 (61.4%)	34 (38.6%)	-
Age		45.2±17.8	45.7±13.4	0.96
Gender	Male	51 (57.9%)	27 (30.7%)	<0.05*
	Female	3 (3.4%)	7 (7.8%)	
Highest serum creatinine		410.0±210.6	397.9±199.3	0.79
Oxygen support		15 (31.3%)	33 (68.8%)	<0.01*
Patients with significant acute haemoglobin reduction		9 (16.7%)	27 (79.4%)	<0.01*
Highest acute haemoglobin reduction prior to transfusion		1.14±1.1	2.8±1.4	<0.01*
Number of patients in ICU		5 (9.3%)	27 (79.4%)	<0.01*
Days in ICU		4± 1.8	7.96±5.4	0.01*
Number of patients with 3 or more major complications		8 (14.8%)	32 (94.1%)	<0.01**
Total hospitalization days		5.57±2.1	11.3±8.2	<0.01**

Mortality	3/54 (5.6%)	12/34 (35.3%)	<0.01*
-----------	----------------	------------------	--------

276

277

278 **Non-invasive and invasive treatment modalities used in patients with severe Leptospirosis**

279 Next, we analysed the treatment modalities used in patients with severe Leptospirosis. All patients
280 received antibiotics. Penicillin, ceftriaxone and doxycycline were the most frequently used
281 antibiotics either alone or in combination: Penicillin or Ceftriaxone monotherapy for 27.3%,
282 penicillin and doxycycline for 13.6%, ceftriaxone and doxycycline for 38.6%. Methylprednisolone
283 was administered to 56(63.6%) and intravenous immunoglobulin (IV Ig) was given to 22(25.0%)
284 patients. Tranexamic acid was given to 49(55.7%) patients.

285 Sixteen (18.2%) patients required dialysis. Two patients required continuous renal replacement
286 therapy (CRRT) concurrently during ECMO. Supplementary oxygen to 55.7%, NIV (CPAP) to
287 21.6% and intubation and ventilation to 36.4%, were required. Plasmapheresis was performed in
288 39(44.3%) and 6 (6.6%) required ECMO.

289 **ECMO in patients with Leptospirosis**

290 ECMO was required in 6 (6.6%) patients with severe pulmonary haemorrhage. Eligibility of
291 ECMO was decided on the severity of respiratory failure calculated by the ‘Murray score’ which
292 consist of PaO₂/FiO₂ (P/F) ratio, extent of alveolar involvement on chest radiograph and peak
293 end-expiratory pressure (PEEP) in the ventilator setting[24], physician’s discretion and the
294 presence of other co-morbidities. All patients had evidence of severe respiratory failure with
295 Murray scores of 3.25 or above and poor oxygenation despite high ventilator settings. They had a
296 mean P/F (paO₂/FiO₂) ratio of 93 before ECMO. All had dense bilateral diffused opacities in the
297 chest radiograph (Supplementary: Figure 1a,b). All underwent veno-venous ECMO and were
298 supported by ECMO for a mean duration of 151.4 hours (\pm 55.83). They were intubated and
299 ventilated for a mean of 12 days (\pm 5.70) and were in ICU for a mean 14.8 \pm 5.44 days (total of 118
300 days). All required renal replacement therapy (RRT). Serial chest radiographs of these patients
301 typically showed resolution of alveolar shadows within 4 to 5 days after initiation of ECMO

302 (Supplementary: Figure 1c,d,e). Four got completely cured and were well at 1- and 3-month
303 follow-up. Two patients succumbed despite ECMO therapy (Supplementary: Table 1).

304 **Overall morbidity and mortality in patients with Leptospirosis**


305 Overall, the mean duration of hospitalization was 8.07(SD±5.9) days. Thirty-two (36.4%)
306 intubated and ventilated and received ICU care for a mean of 6.73 (\pm 4.9) days. Out of them, 17
307 received ICU care for <7days, 4 for 7-14days and 6 for more than 2 weeks. The patients were
308 intubated and ventilated for mean days of 5.97 (SD±4.8) days.

309 The case fatality rate of the study sample was 17% with 15 deaths. Patients who developed PH
310 and FHF had a mortality rate of 35.2% and 54.5%, respectively.

311 The fatality rate of patient with pulmonary haemorrhage who has undergone plasmapheresis is
312 32.3%. Direct comparison for efficacy was not made as the majority (91.2%) of patients with
313 pulmonary haemorrhage have undergone plasmapheresis and only 3 in PH group did not receive
314 plasmapheresis.

315 **Spatial distribution of the abundance of Leptospirosis cases**

316 Total leptospirosis cases, Leptospirosis cases with pulmonary haemorrhage and the number of
317 deaths due to Leptospirosis were mapped for Galle district of Sri Lanka. Figure 1 illustrates that
318 Elpitiya and Yakkalamulla DS divisions are the hot spots for overall leptospirosis cases and
319 Leptospirosis cases with pulmonary haemorrhage (Figure 1 (a) and (b)). On the contrary, Neluwa
320 DS division had the highest death rate due to leptospirosis among all divisions (Figure 1 (c)).



321

322 **Figure 1: The spatial distribution of the cases and deaths of leptospirosis in Galle district,**
 323 **Sri Lanka**

324 **Discussion**

325 In this prospective study, we observed that pulmonary hemorrhage (PH) and hemodynamic
 326 instability early in the presentation were significantly associated with mortality. In Galle, PH were
 327 present in one-third and FHF was present in 12.5% of patients with severe leptospirosis. We
 328 observed that 80% of patients requiring ICU admission had pulmonary hemorrhage, warning us of
 329 the significant morbidity in this group. Hepatic involvement with FHF is considered as an unusual
 330 clinical manifestation of severe leptospirosis[25, 26], and has only been reported in several
 331 instances[21]. Features of fulminant hepatitis were not present early in the illness and developed

332 in patient who require inotropic support which indicate that the pathogenesis could be related to
333 ischaemic liver injury than direct hepatic involvement. However, the presence indicated risk of
334 morbidity and mortality. Therefore, other than the routinely performed hematological tests and
335 renal function tests, we suggest that focused examination and investigations should be performed
336 for early detection of PH and FHF. We suggest to perform prothrombin time (INR), transaminases,
337 hemoglobin reduction, chest radiograph, monitor for hypoxia to identify these complications early.
338 AKI presented as the only manifestation in the majority and other organ complications usually
339 associate with AKI. The presence of a single organ related complication is associated with lesser
340 mortality and with each addition of each organ related complication an increase in mortality is
341 observed. Additionally, we have identified hot spots area of leptospirosis cases and deaths are
342 prevalent in Galle district. This would give us more understanding on how to triage these patients
343 that require strict monitoring and supportive care.

344 Septic shock due to leptospirosis is an under-recognised complication. We also noticed that
345 hemodynamic instability is observed in two-thirds of patients with severe leptospirosis. Most of
346 them required inotropic support, where 50% required 2 or more inotropes. It was observed that the
347 septic shock in Leptospirosis is much difficult to manage than septic shock due to other
348 conventional bacterial organism. However, comparative studies on clinical and cytokine correlated
349 will be of value to understand the pathogenesis. It has been suggested that delay in treating patients
350 with antibiotics and intravenous hydration was an important factor in mortality[28]. Fluid
351 management in severe leptospirosis is more challenging than bacterial sepsis due to the co-
352 occurrence of AKI, myocarditis or multiple organ dysfunction syndrome. Additionally, we should
353 be aware that myocardial dysfunction and severe bleeding can mimic septic shock. Therefore, it
354 has been suggested that a more conservative fluid management approach may be more appropriate
355 in complicated leptospirosis than managing according to standard sepsis guidelines, given the high
356 mortality associated with pulmonary involvement etc[29]. Yilmaz et al. examined ICU patients
357 and found that the clinical and laboratory findings of leptospirosis are similar to those of sepsis.
358 They recommended to think about leptospirosis while examining a patient with SIRS/sepsis
359 etiology in an area endemic for leptospirosis[30]. In a study done in a tropical Australian setting,
360 they have suggested that prompt ICU support, early antibiotics, conservative fluid resuscitation,
361 protective ventilation strategies, traditional thresholds for RRT initiation, and corticosteroid
362 therapy, associated with a very low case-fatality rate[31]. Given the high incidence of

363 hemodynamic instability in our group, we should be more vigilant that septic shock, bleeding and
364 myocarditis should be identified promptly and managed accordingly.

365 Although, we could not find any symptoms present on admission or hematological parameters
366 other than SGOT, that can predict mortality; atrial fibrillation, significant acute hemoglobin
367 reduction, longer duration of shock, requirement of intubation and ICU care were important
368 clinical indicators predicting mortality. It has been reported that disproportionate exaggerated rise
369 of SGOT associated with grave prognosis in the late phase of leptospirosis in a limited number of
370 patients[32]. However, we observed that SGOT can predict mortality at an early phase up to 5 days
371 after the onset of fever.

372 There is a dearth of evidence regarding the extent of hemoglobin reduction detectable in patients
373 with leptospirosis associated pulmonary hemorrhage. We observed that in the PH group, the
374 majority had a significant hemoglobin reduction on 4-6 days after symptom onset. We also
375 observed a mean maximum hemoglobin reduction of 5.6g/dl in patients with PH. This hemoglobin
376 reduction was observed despite efforts to immediately resuscitate and transfuse patients having
377 acute bleeding. Due to the fact that acute hemoglobin reduction predicted mortality, we suggest
378 that it is advisable to cross match 4-5 units of blood upon suspicion of PH. Moreover, in a
379 leptospirosis endemic area of Brazil, they have noted that 13% had gastrointestinal bleeding while
380 a similar percentage developed pulmonary hemorrhages[27]. Therefore, it is plausible that other
381 than pulmonary hemorrhages, leptospirosis could lead to concealed bleeding elsewhere, judging
382 from the fact that significant hemoglobin reduction was observed in nearly 15% of patients who
383 did not have features to suggest pulmonary hemorrhages in our study.

384 As we have only included patients with one or more complication related to leptospirosis, we
385 consider that these patients represent a potentially severe group that needs hospital care and
386 advanced treatment modalities. Moreover, our study includes a large prospective case series of
387 leptospirosis who underwent ECMO in the world. Altogether, there were 11 reported individual
388 cases and two retrospective studies mentioning 13 patients with ARDS due to leptospirosis[22, 32-
389 34] who underwent ECMO. Patients in our study were selected for ECMO when the Murray score
390 was 3-4. ECMO improved oxygenation in these patients who had inadequate oxygenation despite
391 being on maximum ventilatory support. We described 6 patients who underwent ECMO and four
392 survived. Respiratory failure occurring due to pulmonary hemorrhages are transient and reversible,

393 whereas the chances of survival may be improved if they are supported adequately during this
394 critical period. Initiation of ECMO enabled to maintain adequate oxygenation because the lungs
395 could be maintained on ‘rest settings’ at low ventilatory pressures until haemorrhagic lungs
396 recover. Therefore, ‘rest settings’ potentially could reduce inotrope requirement due to restoration
397 of venous return and tissue perfusion due to lesser ventilatory pressures. Due to prevalent septic
398 shock clinical phenotype requiring multiple inotropes, theoretically ECMO would assist to
399 stabilise haemodynamic parameters initially. Traditionally, severe bleeding has been a relative
400 contraindication to extra-corporeal membrane oxygenation (ECMO), which requires systemic
401 anticoagulation to maintain circuit patency. However, cases of diffuse alveolar haemorrhage have
402 been reported to be successfully managed using ECMO[35]. In our case series, standards levels of
403 ACT were used and any aggravation of bleeding was not observed. This should be used cautiously
404 in patients with PH and anticoagulation should be withheld immediately with exacerbation of
405 bleeding. In a tropical setting where funding and resources are sparse, we consider this a major
406 step forward to improve mortality in patients with severe pulmonary haemorrhage due to
407 Leptospirosis.

408 Ideally, further observational studies would have been beneficial to decide on surrogate respiratory
409 parameters (Murray score, P/F ratio, oxygenation index) where ECMO can be initiated. This would
410 invite the need for further research or trials to observe a benefit of ECMO and plasma exchange in
411 patients with pulmonary haemorrhage due to Leptospirosis.

412 **Conclusions**

413 Pulmonary haemorrhage and haemodynamic instability can be used as early predictors of mortality
414 in severe leptospirosis. Other than the above atrial fibrillation, acute haemoglobin reduction,
415 prolonged shock, elevated SGOT level at admission can be used as warning signs of mortality.
416 These findings will have a significant effect on the management of patients in taking decisions on
417 triaging and escalation of care. Identifying disease hot spots of leptospirosis cases and deaths will
418 help in decisions to improve regional hospital facilities and organised transfer for advanced care.

419 **Ethical approval**

420 Ethical approval for the study was obtained from the Ethical Review Committee, Faculty of
421 Medicine, University of Ruhuna. Approval for conducting the research at THK was obtained from
422 the Director of the THK. Informed consent was taken from all study participants.

423 **Author contributions**

424 CLF, NJD, CKB are joint senior authors involved in conceptualisation, conducting and editing of
425 the manuscript. SK analysed the GPS data and created figures. Other authors contributed in patient
426 recruitment, data collection, data analysis and writing initial draft. All authors contributed
427 significantly to this work.

428 **Funding**

429 None.

430 **Acknowledgement**

431 We would like to thank the ECMO team: Dr T Harischandra, Dr K Withanaarachchi and Dr RK
432 Firmin who did an incredible service to facilitate ECMO support and Dr T Weliwita who
433 performed plasma exchange. We are grateful to Dr Lilani Karunanayake and the Medical Research
434 Institute for performing confirmatory investigations to diagnose leptospirosis and also sharing the
435 investigation data with us.

436 **References**

- 437 1. Picardeau M. Leptospirosis: Updating the Global Picture of an Emerging Neglected Disease.
438 PLoS Negl Trop Dis. 2015;9(9):e0004039. doi: 10.1371/journal.pntd.0004039. PubMed PMID:
439 26402855; PubMed Central PMCID: PMC4581693.
- 440 2. Lau CL, Smythe LD, Craig SB, Weinstein P. Climate change, flooding, urbanisation and
441 leptospirosis: fuelling the fire? Trans R Soc Trop Med Hyg. 2010;104(10):631-8. Epub 2010/09/04. doi:
442 10.1016/j.trstmh.2010.07.002. PubMed PMID: 20813388.
- 443 3. Agampodi S, Peacock SJ, Thevanesam V. The potential emergence of leptospirosis in Sri Lanka.
444 The Lancet Infectious diseases. 2009;9(9):524-6. Epub 2009/08/22. doi: 10.1016/s1473-3099(09)70211-
445 7. PubMed PMID: 19695489.
- 446 4. Levett PN. Leptospirosis. Clinical microbiology reviews. 2001;14(2):296-326. doi:
447 10.1128/cmr.14.2.296-326.2001.
- 448 5. Zaki SR, Shieh WJ. Leptospirosis associated with outbreak of acute febrile illness and pulmonary
449 haemorrhage, Nicaragua, 1995. The Epidemic Working Group at Ministry of Health in Nicaragua. Lancet
450 (London, England). 1996;347(9000):535-6. Epub 1996/02/24. PubMed PMID: 8596276.
- 451 6. Segura ER, Ganoza CA, Campos K, Ricaldi JN, Torres S, Silva H, et al. Clinical spectrum of
452 pulmonary involvement in leptospirosis in a region of endemicity, with quantification of leptospiral
453 burden. Clin Infect Dis. 2005;40(3):343-51. Epub 2005/01/26. doi: 10.1086/427110. PubMed PMID:
454 15668855; PubMed Central PMCID: PMC2366057.

- 455 7. Papa A, Theoharidou D, Antoniadis A. Pulmonary involvement and leptospirosis, Greece. *Emerg*
456 *Infect Dis.* 2009;15(5):834-5. Epub 2009/05/01. doi: 10.3201/eid1505.080270. PubMed PMID:
457 19402988; PubMed Central PMCID: PMCPMC2687020.
- 458 8. Gouveia EL, Metcalfe J, de Carvalho AL, Aires TS, Villasboas-Bisneto JC, Queirroz A, et al.
459 Leptospirosis-associated severe pulmonary hemorrhagic syndrome, Salvador, Brazil. *Emerg Infect Dis.*
460 2008;14(3):505-8. Epub 2008/03/08. doi: 10.3201/eid1403.071064. PubMed PMID: 18325275; PubMed
461 Central PMCID: PMCPMC2570821.
- 462 9. McBride AJ, Athanazio DA, Reis MG, Ko AI. Leptospirosis. *Current opinion in infectious*
463 *diseases.* 2005;18(5):376-86. Epub 2005/09/09. PubMed PMID: 16148523.
- 464 10. Devadas S, Das J, Liu C, Zhang L, Roberts AI, Pan Z, et al. Granzyme B is critical for T cell
465 receptor-induced cell death of type 2 helper T cells. *Immunity.* 2006;25(2):237-47. Epub 2006/08/12. doi:
466 10.1016/j.immuni.2006.06.011. PubMed PMID: 16901729.
- 467 11. Panaphut T, Domrongkitchaiporn S, Thinkamrop B. Prognostic factors of death in leptospirosis: a
468 prospective cohort study in Khon Kaen, Thailand. *Int J Infect Dis.* 2002;6(1):52-9. Epub 2002/06/05.
469 PubMed PMID: 12044303.
- 470 12. Marotto PC, Nascimento CM, Eluf-Neto J, Marotto MS, Andrade L, Sztajnbok J, et al. Acute
471 lung injury in leptospirosis: clinical and laboratory features, outcome, and factors associated with
472 mortality. *Clin Infect Dis.* 1999;29(6):1561-3. Epub 1999/12/10. doi: 10.1086/313501. PubMed PMID:
473 10585813.
- 474 13. Warnasekara J, Koralegedara I, Agampodi S. Estimating the burden of leptospirosis in Sri Lanka;
475 a systematic review. *BMC Infect Dis.* 2019;19(1):119. Epub 2019/02/08. doi: 10.1186/s12879-018-3655-
476 y. PubMed PMID: 30727968; PubMed Central PMCID: PMCPMC6364467.
- 477 14. Herath N, Uluwattage W, Weliwitiya T, Karunanayake L, Lekamwasam S, Ratnatunga N, et al.
478 Sequel and therapeutic modalities of leptospirosis associated severe pulmonary haemorrhagic syndrome
479 (SPHS); a Sri Lankan experience. *BMC Infect Dis.* 2019;19(1):451. Epub 2019/05/23. doi:
480 10.1186/s12879-019-4094-0. PubMed PMID: 31113404; PubMed Central PMCID: PMCPMC6530063.
- 481 15. Ko AI, Galvão Reis M, Ribeiro Dourado CM, Johnson WD, Jr., Riley LW. Urban epidemic of
482 severe leptospirosis in Brazil. *Salvador Leptospirosis Study Group. Lancet (London, England).*
483 1999;354(9181):820-5. Epub 1999/09/15. doi: 10.1016/s0140-6736(99)80012-9. PubMed PMID:
484 10485724.
- 485 16. Haake DA, Levett PN. Leptospirosis in humans. *Current topics in microbiology and immunology.*
486 2015;387:65-97. doi: 10.1007/978-3-662-45059-8_5. PubMed PMID: 25388133.
- 487 17. Pappachan MJ, Mathew S, Aravindan KP, Khader A, Bharghavan PV, Kareem MM, et al. Risk
488 factors for mortality in patients with leptospirosis during an epidemic in northern Kerala. *Natl Med J*
489 *India.* 2004;17(5):240-2. Epub 2005/01/11. PubMed PMID: 15638302.
- 490 18. Al Hariri YK, Sulaiman SAS, Khan AH, Adnan AS, Al Ebrahim SQ. Mortality of leptospirosis
491 associated acute kidney injury (LAKI) & predictors for its development in adults: A systematic review.
492 *Journal of Infection and Public Health.* 2019;12(6):751-9. doi: <https://doi.org/10.1016/j.jiph.2019.06.014>.
- 493 19. Agampodi SB, Dahanayaka NJ, Bandaranayaka AK, Perera M, Priyankara S, Weerawansa P, et
494 al. Regional differences of leptospirosis in Sri Lanka: observations from a flood-associated outbreak in
495 2011. *PLoS Negl Trop Dis.* 2014;8(1):e2626. doi: 10.1371/journal.pntd.0002626. PubMed PMID:
496 24454971; PubMed Central PMCID: PMCPMC3894175.
- 497 20. Dassanayake DL, Wimalaratna H, Nandadewa D, Nugaliyadda A, Ratnatunga CN, Agampodi
498 SB. Predictors of the development of myocarditis or acute renal failure in patients with leptospirosis: an
499 observational study. *BMC Infect Dis.* 2012;12:4. Epub 2012/01/17. doi: 10.1186/1471-2334-12-4.
500 PubMed PMID: 22243770; PubMed Central PMCID: PMCPMC3292442.
- 501 21. Shintaku M, Itoh H, Tsutsumi Y. Weil's disease (leptospirosis) manifesting as fulminant hepatic
502 failure: Report of an autopsy case. *Pathology - Research and Practice.* 2014;210(12):1134-7. doi:
503 <https://doi.org/10.1016/j.prp.2014.05.002>.

- 504 22. Fonseka CL, Lekamwasam S. Role of Plasmapheresis and Extracorporeal Membrane
505 Oxygenation in the Treatment of Leptospirosis Complicated with Pulmonary Hemorrhages. *Journal of*
506 *Tropical Medicine*. 2018;2018:8. doi: 10.1155/2018/4520185.
- 507 23. Organization WH. Report of the first meeting of the leptospirosis burden epidemiology reference
508 group. 2010.
- 509 24. Organization ELS. ELSO Guidelines for Cardiopulmonary Extracorporeal Life Support
510 (Version 1.4).
- 511 25. Spichler AS, Vilaça PJ, Athanazio DA, Albuquerque JOM, Buzzar M, Castro B, et al. Predictors
512 of lethality in severe leptospirosis in urban Brazil. *The American journal of tropical medicine and*
513 *hygiene*. 2008;79(6):911-4. PubMed PMID: 19052303.
- 514 26. Wang HK, Lee MH, Chen YC, Hsueh PR, Chang SC. Factors associated with severity and
515 mortality in patients with confirmed leptospirosis at a regional hospital in northern Taiwan. *J Microbiol*
516 *Immunol Infect*. 2018. Epub 2018/06/24. doi: 10.1016/j.jmii.2018.05.005. PubMed PMID: 29934034.
- 517 27. Daher EF, Lima RS, Silva Júnior GB, Silva EC, Karbage NN, Kataoka RS, et al. Clinical
518 presentation of leptospirosis: a retrospective study of 201 patients in a metropolitan city of Brazil. *Braz J*
519 *Infect Dis*. 2010;14(1):3-10. Epub 2010/04/30. PubMed PMID: 20428646.
- 520 28. Duarte-Neto AN, Croda J, Pagliari C, Soriano FG, Nicodemo AC, Duarte MIS. Severe
521 Leptospirosis Features in the Spleen Indicate Cellular Immunosuppression Similar to That Found in
522 Septic Shock. *Frontiers in immunology*. 2019;10:920-. doi: 10.3389/fimmu.2019.00920. PubMed PMID:
523 31114579.
- 524 29. Niwattayakul K, Homvijitkul J, Niwattayakul S, Khaw O, Sitprijia V. Hypotension, renal failure,
525 and pulmonary complications in leptospirosis. *Ren Fail*. 2002;24(3):297-305. Epub 2002/08/09. doi:
526 10.1081/jdi-120005363. PubMed PMID: 12166696.
- 527 30. Yilmaz H, Turhan V, Yasar KK, Hatipoglu M, Sunbul M, Leblebicioglu H. Characteristics of
528 leptospirosis with systemic inflammatory response syndrome: a multicenter study. *Annals of clinical*
529 *microbiology and antimicrobials*. 2015;14:54-. doi: 10.1186/s12941-015-0117-x. PubMed PMID:
530 26690093.
- 531 31. Smith S, Liu Y-H, Carter A, Kennedy BJ, Dermedoglou A, Poulgrain SS, et al. Severe
532 leptospirosis in tropical Australia: Optimising intensive care unit management to reduce mortality. *PLoS*
533 *neglected tropical diseases*. 2019;13(12):e0007929-e. doi: 10.1371/journal.pntd.0007929. PubMed PMID:
534 31790405.
- 535 32. Delmas B, Jabot J, Chanareille P, Ferdynus C, Allyn J, Allou N, et al. Leptospirosis in ICU: A
536 Retrospective Study of 134 Consecutive Admissions. *Crit Care Med*. 2018;46(1):93-9. doi:
537 10.1097/CCM.0000000000002825. PubMed PMID: 29116996.
- 538 33. Barnacle J, Gurney S, Ledot S, Singh S. Leptospirosis as an important differential of pulmonary
539 haemorrhage on the intensive care unit: a case managed with VV-ECMO. *J Intensive Care*. 2020;8:31.
540 Epub 2020/05/01. doi: 10.1186/s40560-020-00447-2. PubMed PMID: 32351698; PubMed Central
541 PMCID: PMC7183660.
- 542 34. Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, et al. Efficacy and
543 economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation
544 for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. *Lancet (London,*
545 *England)*. 2009;374(9698):1351-63. Epub 2009/09/19. doi: 10.1016/s0140-6736(09)61069-2. PubMed
546 PMID: 19762075.
- 547 35. Abrams D, Agerstrand CL, Biscotti M, Burkart KM, Bacchetta M, Brodie D. Extracorporeal
548 membrane oxygenation in the management of diffuse alveolar hemorrhage. *Asaio j*. 2015;61(2):216-8.
549 Epub 2014/12/09. doi: 10.1097/mat.000000000000183. PubMed PMID: 25485559.

550